Blood:成人高级别B细胞淋巴瘤与Burkitt淋巴瘤:基因组特征和潜在的治疗靶点

2017-08-12 qinqiyun MedSci原创

与儿童mBL相比,成人-mBLs有明显而又更高频率的DNA拷贝数变异。基因综合分析提示BCR信号通路是治疗成人mBL潜在靶点。

中心点:

儿童mBL相比,成人-mBLs有明显而又更高频率的DNA拷贝数变异。

基因综合分析提示BCR信号通路是治疗成人mBL潜在靶点。

摘要:

成人高级别B细胞淋巴瘤与伯基特淋巴瘤(BL)分子特征相似,均是高度侵袭性淋巴瘤,临床预后不良。携带BL基因的成人BL和高级别B细胞淋巴瘤的高分辨率结构性和功能性基因组分析揭示MYC-ARF-p53轴是主要解除控制的信号通路。

儿童-mBL相比,成人-mBL携带明显而又高频的基因异常(del13q14, del17p, gain8q24和gain18q21)。基因突变对tonic B细胞受体(BCR)-PI3K信号通路的促进作用与年龄没有关系,而BCR-NF-κB慢信号的作用与成人-mBL相关。成人-mBL的一个子集携带BCL2异位和突变,上调BCL2 mRNA和蛋白质表达,其中一个突变图谱与mBL相似。这些被双重打击的淋巴瘤可能来源于携带BCL2和MYC易位和/或KMT2D(MLL2)突变的肿瘤前体。在50%的成人-mBL患者中观察到MIR17HG和它的旁系同源位点的获得/扩增。

体外实验证实miR-17~92在BCR信号通路的活性和对依鲁替尼的敏感性中发挥作用。综合分析验证受CN和突变影响的相关基因网络,导致p53信号通路和BCR-PI3K/NF-κB活性的破坏。这一发现需要进行体内实验进一步验证。

原始出处:

Alyssa Bouska,Chengfeng Bi,et al.Adult High Grade B-cell Lymphoma with Burkitt Lymphoma Signature: Genomic features and Potential Therapeutic Targets.Blood.August 11,2017.https://doi.org/10.1182/blood-2017-02-767335

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1895336, encodeId=dc531895336d2, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Feb 22 09:14:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702425, encodeId=43891e02425d3, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed Dec 13 09:14:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703035, encodeId=5bcf1e03035a5, content=<a href='/topic/show?id=3b2d3e9256' target=_blank style='color:#2F92EE;'>#Burkitt淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3792, encryptionId=3b2d3e9256, topicName=Burkitt淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b2330471122, createdName=yulin2016, createdTime=Fri Dec 08 15:14:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273208, encodeId=124612e32082c, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Mon Aug 14 05:14:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585472, encodeId=984015854e2bd, content=<a href='/topic/show?id=f19310515b9' target=_blank style='color:#2F92EE;'>#KIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10515, encryptionId=f19310515b9, topicName=KIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8ff17204571, createdName=shuangle, createdTime=Mon Aug 14 05:14:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233193, encodeId=faa7233193d0, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Sun Aug 13 16:38:28 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233019, encodeId=f93a2330190e, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Aug 13 05:52:18 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232902, encodeId=84962329024b, content=学习了不少事情!, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Sat Aug 12 16:29:31 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232893, encodeId=e80823289378, content=吃货滚滚滚滚滚, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEKXpC8j9TaoCpG4yIB3skibUZ0ricmVQ6KKIVpqYQxINrmlibsPZSia7GOUupzuINf8UITMib8awsjjkPw/0, createdBy=abbf1713451, createdName=zt123, createdTime=Sat Aug 12 15:38:09 CST 2017, time=2017-08-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1895336, encodeId=dc531895336d2, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Feb 22 09:14:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702425, encodeId=43891e02425d3, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed Dec 13 09:14:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703035, encodeId=5bcf1e03035a5, content=<a href='/topic/show?id=3b2d3e9256' target=_blank style='color:#2F92EE;'>#Burkitt淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3792, encryptionId=3b2d3e9256, topicName=Burkitt淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b2330471122, createdName=yulin2016, createdTime=Fri Dec 08 15:14:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273208, encodeId=124612e32082c, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Mon Aug 14 05:14:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585472, encodeId=984015854e2bd, content=<a href='/topic/show?id=f19310515b9' target=_blank style='color:#2F92EE;'>#KIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10515, encryptionId=f19310515b9, topicName=KIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8ff17204571, createdName=shuangle, createdTime=Mon Aug 14 05:14:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233193, encodeId=faa7233193d0, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Sun Aug 13 16:38:28 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233019, encodeId=f93a2330190e, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Aug 13 05:52:18 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232902, encodeId=84962329024b, content=学习了不少事情!, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Sat Aug 12 16:29:31 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232893, encodeId=e80823289378, content=吃货滚滚滚滚滚, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEKXpC8j9TaoCpG4yIB3skibUZ0ricmVQ6KKIVpqYQxINrmlibsPZSia7GOUupzuINf8UITMib8awsjjkPw/0, createdBy=abbf1713451, createdName=zt123, createdTime=Sat Aug 12 15:38:09 CST 2017, time=2017-08-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1895336, encodeId=dc531895336d2, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Feb 22 09:14:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702425, encodeId=43891e02425d3, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed Dec 13 09:14:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703035, encodeId=5bcf1e03035a5, content=<a href='/topic/show?id=3b2d3e9256' target=_blank style='color:#2F92EE;'>#Burkitt淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3792, encryptionId=3b2d3e9256, topicName=Burkitt淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b2330471122, createdName=yulin2016, createdTime=Fri Dec 08 15:14:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273208, encodeId=124612e32082c, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Mon Aug 14 05:14:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585472, encodeId=984015854e2bd, content=<a href='/topic/show?id=f19310515b9' target=_blank style='color:#2F92EE;'>#KIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10515, encryptionId=f19310515b9, topicName=KIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8ff17204571, createdName=shuangle, createdTime=Mon Aug 14 05:14:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233193, encodeId=faa7233193d0, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Sun Aug 13 16:38:28 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233019, encodeId=f93a2330190e, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Aug 13 05:52:18 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232902, encodeId=84962329024b, content=学习了不少事情!, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Sat Aug 12 16:29:31 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232893, encodeId=e80823289378, content=吃货滚滚滚滚滚, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEKXpC8j9TaoCpG4yIB3skibUZ0ricmVQ6KKIVpqYQxINrmlibsPZSia7GOUupzuINf8UITMib8awsjjkPw/0, createdBy=abbf1713451, createdName=zt123, createdTime=Sat Aug 12 15:38:09 CST 2017, time=2017-08-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1895336, encodeId=dc531895336d2, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Feb 22 09:14:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702425, encodeId=43891e02425d3, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed Dec 13 09:14:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703035, encodeId=5bcf1e03035a5, content=<a href='/topic/show?id=3b2d3e9256' target=_blank style='color:#2F92EE;'>#Burkitt淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3792, encryptionId=3b2d3e9256, topicName=Burkitt淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b2330471122, createdName=yulin2016, createdTime=Fri Dec 08 15:14:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273208, encodeId=124612e32082c, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Mon Aug 14 05:14:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585472, encodeId=984015854e2bd, content=<a href='/topic/show?id=f19310515b9' target=_blank style='color:#2F92EE;'>#KIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10515, encryptionId=f19310515b9, topicName=KIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8ff17204571, createdName=shuangle, createdTime=Mon Aug 14 05:14:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233193, encodeId=faa7233193d0, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Sun Aug 13 16:38:28 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233019, encodeId=f93a2330190e, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Aug 13 05:52:18 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232902, encodeId=84962329024b, content=学习了不少事情!, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Sat Aug 12 16:29:31 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232893, encodeId=e80823289378, content=吃货滚滚滚滚滚, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEKXpC8j9TaoCpG4yIB3skibUZ0ricmVQ6KKIVpqYQxINrmlibsPZSia7GOUupzuINf8UITMib8awsjjkPw/0, createdBy=abbf1713451, createdName=zt123, createdTime=Sat Aug 12 15:38:09 CST 2017, time=2017-08-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1895336, encodeId=dc531895336d2, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Feb 22 09:14:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702425, encodeId=43891e02425d3, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed Dec 13 09:14:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703035, encodeId=5bcf1e03035a5, content=<a href='/topic/show?id=3b2d3e9256' target=_blank style='color:#2F92EE;'>#Burkitt淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3792, encryptionId=3b2d3e9256, topicName=Burkitt淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b2330471122, createdName=yulin2016, createdTime=Fri Dec 08 15:14:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273208, encodeId=124612e32082c, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Mon Aug 14 05:14:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585472, encodeId=984015854e2bd, content=<a href='/topic/show?id=f19310515b9' target=_blank style='color:#2F92EE;'>#KIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10515, encryptionId=f19310515b9, topicName=KIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8ff17204571, createdName=shuangle, createdTime=Mon Aug 14 05:14:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233193, encodeId=faa7233193d0, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Sun Aug 13 16:38:28 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233019, encodeId=f93a2330190e, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Aug 13 05:52:18 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232902, encodeId=84962329024b, content=学习了不少事情!, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Sat Aug 12 16:29:31 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232893, encodeId=e80823289378, content=吃货滚滚滚滚滚, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEKXpC8j9TaoCpG4yIB3skibUZ0ricmVQ6KKIVpqYQxINrmlibsPZSia7GOUupzuINf8UITMib8awsjjkPw/0, createdBy=abbf1713451, createdName=zt123, createdTime=Sat Aug 12 15:38:09 CST 2017, time=2017-08-12, status=1, ipAttribution=)]
    2017-08-14 shuangle
  6. [GetPortalCommentsPageByObjectIdResponse(id=1895336, encodeId=dc531895336d2, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Feb 22 09:14:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702425, encodeId=43891e02425d3, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed Dec 13 09:14:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703035, encodeId=5bcf1e03035a5, content=<a href='/topic/show?id=3b2d3e9256' target=_blank style='color:#2F92EE;'>#Burkitt淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3792, encryptionId=3b2d3e9256, topicName=Burkitt淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b2330471122, createdName=yulin2016, createdTime=Fri Dec 08 15:14:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273208, encodeId=124612e32082c, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Mon Aug 14 05:14:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585472, encodeId=984015854e2bd, content=<a href='/topic/show?id=f19310515b9' target=_blank style='color:#2F92EE;'>#KIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10515, encryptionId=f19310515b9, topicName=KIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8ff17204571, createdName=shuangle, createdTime=Mon Aug 14 05:14:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233193, encodeId=faa7233193d0, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Sun Aug 13 16:38:28 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233019, encodeId=f93a2330190e, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Aug 13 05:52:18 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232902, encodeId=84962329024b, content=学习了不少事情!, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Sat Aug 12 16:29:31 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232893, encodeId=e80823289378, content=吃货滚滚滚滚滚, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEKXpC8j9TaoCpG4yIB3skibUZ0ricmVQ6KKIVpqYQxINrmlibsPZSia7GOUupzuINf8UITMib8awsjjkPw/0, createdBy=abbf1713451, createdName=zt123, createdTime=Sat Aug 12 15:38:09 CST 2017, time=2017-08-12, status=1, ipAttribution=)]
    2017-08-13 三生有幸9135

    学习一下谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1895336, encodeId=dc531895336d2, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Feb 22 09:14:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702425, encodeId=43891e02425d3, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed Dec 13 09:14:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703035, encodeId=5bcf1e03035a5, content=<a href='/topic/show?id=3b2d3e9256' target=_blank style='color:#2F92EE;'>#Burkitt淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3792, encryptionId=3b2d3e9256, topicName=Burkitt淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b2330471122, createdName=yulin2016, createdTime=Fri Dec 08 15:14:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273208, encodeId=124612e32082c, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Mon Aug 14 05:14:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585472, encodeId=984015854e2bd, content=<a href='/topic/show?id=f19310515b9' target=_blank style='color:#2F92EE;'>#KIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10515, encryptionId=f19310515b9, topicName=KIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8ff17204571, createdName=shuangle, createdTime=Mon Aug 14 05:14:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233193, encodeId=faa7233193d0, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Sun Aug 13 16:38:28 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233019, encodeId=f93a2330190e, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Aug 13 05:52:18 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232902, encodeId=84962329024b, content=学习了不少事情!, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Sat Aug 12 16:29:31 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232893, encodeId=e80823289378, content=吃货滚滚滚滚滚, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEKXpC8j9TaoCpG4yIB3skibUZ0ricmVQ6KKIVpqYQxINrmlibsPZSia7GOUupzuINf8UITMib8awsjjkPw/0, createdBy=abbf1713451, createdName=zt123, createdTime=Sat Aug 12 15:38:09 CST 2017, time=2017-08-12, status=1, ipAttribution=)]
    2017-08-13 130****4638

    学习了谢谢分享

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1895336, encodeId=dc531895336d2, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Feb 22 09:14:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702425, encodeId=43891e02425d3, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed Dec 13 09:14:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703035, encodeId=5bcf1e03035a5, content=<a href='/topic/show?id=3b2d3e9256' target=_blank style='color:#2F92EE;'>#Burkitt淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3792, encryptionId=3b2d3e9256, topicName=Burkitt淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b2330471122, createdName=yulin2016, createdTime=Fri Dec 08 15:14:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273208, encodeId=124612e32082c, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Mon Aug 14 05:14:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585472, encodeId=984015854e2bd, content=<a href='/topic/show?id=f19310515b9' target=_blank style='color:#2F92EE;'>#KIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10515, encryptionId=f19310515b9, topicName=KIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8ff17204571, createdName=shuangle, createdTime=Mon Aug 14 05:14:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233193, encodeId=faa7233193d0, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Sun Aug 13 16:38:28 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233019, encodeId=f93a2330190e, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Aug 13 05:52:18 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232902, encodeId=84962329024b, content=学习了不少事情!, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Sat Aug 12 16:29:31 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232893, encodeId=e80823289378, content=吃货滚滚滚滚滚, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEKXpC8j9TaoCpG4yIB3skibUZ0ricmVQ6KKIVpqYQxINrmlibsPZSia7GOUupzuINf8UITMib8awsjjkPw/0, createdBy=abbf1713451, createdName=zt123, createdTime=Sat Aug 12 15:38:09 CST 2017, time=2017-08-12, status=1, ipAttribution=)]
    2017-08-12 圣艮山

    学习了不少事情!

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1895336, encodeId=dc531895336d2, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Thu Feb 22 09:14:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702425, encodeId=43891e02425d3, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed Dec 13 09:14:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703035, encodeId=5bcf1e03035a5, content=<a href='/topic/show?id=3b2d3e9256' target=_blank style='color:#2F92EE;'>#Burkitt淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3792, encryptionId=3b2d3e9256, topicName=Burkitt淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b2330471122, createdName=yulin2016, createdTime=Fri Dec 08 15:14:00 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273208, encodeId=124612e32082c, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Mon Aug 14 05:14:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585472, encodeId=984015854e2bd, content=<a href='/topic/show?id=f19310515b9' target=_blank style='color:#2F92EE;'>#KIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10515, encryptionId=f19310515b9, topicName=KIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8ff17204571, createdName=shuangle, createdTime=Mon Aug 14 05:14:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233193, encodeId=faa7233193d0, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Sun Aug 13 16:38:28 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233019, encodeId=f93a2330190e, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sun Aug 13 05:52:18 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232902, encodeId=84962329024b, content=学习了不少事情!, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4BGdu4COj6QWFqgMd3xnWDdgLZKUGI32veZvO2qFAQvpYr1eMbUOTqMvlZWc3MsugtFMHzxDwial/0, createdBy=88731939304, createdName=圣艮山, createdTime=Sat Aug 12 16:29:31 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232893, encodeId=e80823289378, content=吃货滚滚滚滚滚, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEKXpC8j9TaoCpG4yIB3skibUZ0ricmVQ6KKIVpqYQxINrmlibsPZSia7GOUupzuINf8UITMib8awsjjkPw/0, createdBy=abbf1713451, createdName=zt123, createdTime=Sat Aug 12 15:38:09 CST 2017, time=2017-08-12, status=1, ipAttribution=)]
    2017-08-12 zt123

    吃货滚滚滚滚滚

    0

相关资讯

利妥昔单抗联合苯达莫司汀或可治疗侵袭性B细胞淋巴瘤

来源:医学论坛网   《肿瘤学年鉴》(Ann Oncol)近期发表的一项研究表明,不适合R-CHOP(利妥昔单抗+环磷酰胺+多柔比星+长春新碱+泼尼松)治疗的高龄侵袭性B细胞淋巴瘤(BCL)患者或可选择利妥昔单抗联合苯达莫司汀进行治疗。但是,这一结果需要更大规模研究来证实。   该研究是一项Ⅱ期研究,在不适合R-CHOP治疗或不愿意接受损伤性治疗的老年(≥80岁)患者中评估了采用利妥

2017 NCCN临床实践指南:B细胞淋巴瘤(2017.V1)

2016年12月,美国国家综合癌症网络(NCCN)发布了B细胞淋巴瘤指南2017年第1版。全文获取:下载地址:指南下载 (需要扣积分2分, 梅斯医学APP免积分下载) 

[ASH 2016]B细胞淋巴瘤临床研究进展

2016年第58届美国血液学会(ASH)年会上,不少B细胞淋巴瘤领域的重要临床研究发布了最新研究结果,有的甚至可能会改变我们目前的临床路径。文章将就弥漫大B细胞淋巴瘤(DLBCL)和套细胞淋巴瘤(MCL)的几个主要前瞻性临床研究结果进行总结。一、DLBCL利妥昔单抗(rituximab)联合CHOP方案是目前推荐的DLBCL一线治疗方案,后来发现R-DA-EPOCH方案能明显提高原发纵隔DLB

NCCN临床实践指南:B细胞淋巴瘤(2017.V3)

内容介绍: 2017年3月,美国国家综合癌症网络(NCCN)发布了B细胞淋巴瘤指南2017年第3版,指南更新摘要如下: 滤泡淋巴瘤 边缘区淋巴瘤 套细胞淋巴瘤 弥漫性大B细胞淋巴瘤 伯基特淋巴瘤 AIDS相关性淋巴瘤 淋巴母细胞性淋巴瘤 移植术后淋巴组织增生性疾病 巨淋巴结增生症 使用免疫表型/基因型检测鉴别诊断成熟B-细胞和NK/T细胞肿瘤 B细胞淋巴瘤

Blood : pembrolizumab治疗B细胞淋巴瘤的安全性和耐受性

使用pembrolizumab阻断PD-1对rrPMBCL具有可控的安全性和理想的抗肿瘤活性。

Blood:以BCL-2为靶点治疗B细胞淋巴瘤的进展。

近日,一种高潜力、高选择性口服BCL-2拮抗剂——Venetoclax——被批准用于治疗慢性淋巴细胞性白血病(CLL),已证实其在CLL具有高效性,即使是在携带高风险因子del(17p)的患者。此外,也已证实Venetoclax在B淋巴细胞性非霍奇金淋巴瘤(NHL)的其他亚型也是有效的,特别是在套细胞淋巴瘤(MCL)和滤泡性淋巴瘤(FL)。